Syros Pharmaceuticals (SYRS) Revenue & Revenue Breakdown
Syros Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$9.94M
Syros Pharmaceuticals Revenue by Period
Syros Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $9.94M | -33.23% |
| 2022-12-31 | $14.88M | -36.65% |
| 2021-12-31 | $23.49M | 55.62% |
| 2020-12-31 | $15.09M | 661.50% |
| 2019-12-31 | $1.98M | -3.32% |
| 2018-12-31 | $2.05M | 86.19% |
| 2017-12-31 | $1.10M | 247.32% |
| 2016-12-31 | $317.00K | - |
| 2015-12-31 | $317.00K | 100.00% |
| 2014-12-31 | - | - |
Syros Pharmaceuticals generated $9.94M in revenue during NA 2023, up -33.23% compared to the previous quarter, and up 484.68% compared to the same period a year ago.
Syros Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $386.00K | -89.74% |
| 2023-09-30 | $3.76M | 32.79% |
| 2023-06-30 | $2.83M | -4.10% |
| 2023-03-31 | $2.95M | -154.03% |
| 2022-12-31 | $-5.47M | -240.50% |
| 2022-09-30 | $3.89M | -38.00% |
| 2022-06-30 | $6.28M | 14.80% |
| 2022-03-31 | $5.47M | -29.93% |
| 2021-12-31 | $7.80M | 36.95% |
| 2021-09-30 | $5.70M | 10.36% |
| 2021-06-30 | $5.16M | 6.94% |
| 2021-03-31 | $4.83M | -15.30% |
| 2020-12-31 | $5.70M | 48.88% |
| 2020-09-30 | $3.83M | 20.08% |
| 2020-06-30 | $3.19M | 34.01% |
| 2020-03-31 | $2.38M | 368.31% |
| 2019-12-31 | $508.00K | -8.96% |
| 2019-09-30 | $558.00K | 20.78% |
| 2019-06-30 | $462.00K | 1.76% |
| 2019-03-31 | $454.00K | -49.16% |
| 2018-12-31 | $893.00K | 116.75% |
| 2018-09-30 | $412.00K | 9.87% |
| 2018-06-30 | $375.00K | 1.35% |
| 2018-03-31 | $370.00K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | -100.00% |
| 2017-03-31 | $1.10M | 247.32% |
| 2016-12-31 | $317.00K | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | -100.00% |
| 2015-06-30 | $317.00K | 100.00% |
| 2015-03-31 | - | - |
Syros Pharmaceuticals generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Syros Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CHRS | Coherus BioSciences | $257.24M | $70.77M |
| XNCR | Xencor | $168.34M | $16.96M |
| SPRO | Spero Therapeutics | $96.73M | $13.47M |
| RGNX | REGENXBIO | $90.24M | $24.20M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| SYRS | Syros Pharmaceuticals | $9.94M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.14M |
| KZR | Kezar Life Sciences | $7.00M | - |
| KRON | Kronos Bio | $6.29M | $2.37M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | - |
| FIXX | Q32 Bio | $1.16M | - |
| KROS | Keros Therapeutics | $151.00K | $37.00K |
| BDTX | Black Diamond Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| PASG | Passage Bio | - | - |
| SNDX | Syndax Pharmaceuticals | - | $12.50M |
| RNXT | RenovoRx | - | - |
| NLTX | Neurogene | - | - |
| LRMR | Larimar Therapeutics | - | - |
| SRZN | Surrozen | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
| KTTA | Pasithea Therapeutics | - | - |